Details
Stereochemistry | ACHIRAL |
Molecular Formula | C16H12O4 |
Molecular Weight | 268.2641 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CC1=CC2=C(C=C1)C(=O)C3=C(CO2)C=CC=C3
InChI
InChIKey=PYIHCGFQQSKYBO-UHFFFAOYSA-N
InChI=1S/C16H12O4/c17-15(18)8-10-5-6-13-14(7-10)20-9-11-3-1-2-4-12(11)16(13)19/h1-7H,8-9H2,(H,17,18)
Oxepinac was developed as an anti-inflammatory drug. Results of clinical trials have revealed that oxepinac was an effective and well-tolerated drug in the treatment of painful osteoarthritis. Experiments on animal have shown that oxepinac had no teratogenic effect on fetuses in mice and rabbits. Information about the current use of this drug is not available.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Acute, subacute and chronic toxicity of oxepinac. | 1978 |
|
Nonsteroidal antiinflammatory agents. 2. Derivatives/analogues of dibenz[b,e]oxepin-3-acetic acid. | 1978 Jul |
|
Quantitative analysis of oxepinac in human plasma, urine and saliva by gas chromatography--mass fragmentography. | 1980 Apr 11 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/350232
Male 31, female 104, and the age distribution are 37--82 years and 62 years in average. Three groups of the doses, 75 mg, 150 mg, 300 mg daily, respectively, were administered for two weeks.
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C257
Created by
admin on Sat Dec 16 16:23:08 GMT 2023 , Edited by admin on Sat Dec 16 16:23:08 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB09515MIG
Created by
admin on Sat Dec 16 16:23:08 GMT 2023 , Edited by admin on Sat Dec 16 16:23:08 GMT 2023
|
PRIMARY | |||
|
100000083057
Created by
admin on Sat Dec 16 16:23:08 GMT 2023 , Edited by admin on Sat Dec 16 16:23:08 GMT 2023
|
PRIMARY | |||
|
41531
Created by
admin on Sat Dec 16 16:23:08 GMT 2023 , Edited by admin on Sat Dec 16 16:23:08 GMT 2023
|
PRIMARY | |||
|
DTXSID10204219
Created by
admin on Sat Dec 16 16:23:08 GMT 2023 , Edited by admin on Sat Dec 16 16:23:08 GMT 2023
|
PRIMARY | |||
|
C66260
Created by
admin on Sat Dec 16 16:23:08 GMT 2023 , Edited by admin on Sat Dec 16 16:23:08 GMT 2023
|
PRIMARY | |||
|
4111
Created by
admin on Sat Dec 16 16:23:08 GMT 2023 , Edited by admin on Sat Dec 16 16:23:08 GMT 2023
|
PRIMARY | |||
|
CHEMBL312109
Created by
admin on Sat Dec 16 16:23:08 GMT 2023 , Edited by admin on Sat Dec 16 16:23:08 GMT 2023
|
PRIMARY | |||
|
PF3750D8AE
Created by
admin on Sat Dec 16 16:23:08 GMT 2023 , Edited by admin on Sat Dec 16 16:23:08 GMT 2023
|
PRIMARY | |||
|
55689-65-1
Created by
admin on Sat Dec 16 16:23:08 GMT 2023 , Edited by admin on Sat Dec 16 16:23:08 GMT 2023
|
PRIMARY |
ACTIVE MOIETY